Of investors’ many concerns about Valeant Pharmaceuticals and its relationship with a specialty pharmacy, one has stood out: Why is Valeant talking about this only now? Until this week, Valeant’s disclosures on the subject were slim.
from WSJ.com: US Business http://ift.tt/1LTekmP
via IFTTT
No comments:
Post a Comment